AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (1.4 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Rapid Communication | Open Access

An in-depth analysis of the prognostic significance and potential clinical impact of Leupaxin in the immunotherapeutic treatment of esophageal squamous cell carcinoma

Fei Tenga,1Yang Chena,1Xiaojuan ZhangbHai-Ke LeiaMei HeaWei WangaZhi-Qiang Wanga( )Gui-Xue Wangb( )
Key Laboratory for Biorheological Science and Technology of Ministry of Education (Chongqing University), Chongqing University Cancer Hospital, Chongqing 400030, China
Key Laboratory for Biorheological Science and Technology of Ministry of Education, State and Local Joint Engineering Lab for Vascular Implants, College of Bioengineering, Chongqing University, Chongqing 400044, China

1 These authors have contributed equally to this work.

Peer review under responsibility of Chongqing Medical University.

Show Author Information

References

【1】
【1】
 
 
Genes & Diseases

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Teng F, Chen Y, Zhang X, et al. An in-depth analysis of the prognostic significance and potential clinical impact of Leupaxin in the immunotherapeutic treatment of esophageal squamous cell carcinoma. Genes & Diseases, 2026, 13(1). https://doi.org/10.1016/j.gendis.2025.101695

132

Views

1

Downloads

0

Crossref

0

Web of Science

0

Scopus

0

CSCD

Received: 07 June 2024
Published: 27 May 2025
© 2025 The Authors.

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).